- Raw materials
- Barbiturates
- Valnoctamide
Valnoctamide API Manufacturers & Suppliers
0 verified results
All Valnoctamide data. Full access. Full negotiation power
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Valnoctamide | CAS No: 4171-13-5 | GMP-certified suppliers
A medication that is investigated for managing psychiatric disorders such as Mania and Schizoaffective Disorder, offering potential central nervous system depressant effects for affective and psychotic conditions.
Therapeutic categories
Product Snapshot
- Valnoctamide is an oral small molecule formulation
- It is primarily used for neurological and psychiatric therapeutic applications
- The compound is currently in the investigational stage and has not received FDA or EMA approval
Clinical Overview
Although valnoctamide’s precise pharmacological profile, mechanism of action, and pharmacodynamics are not definitively characterized, it is classified among central nervous system depressants, including hypnotics and sedatives. These categorizations suggest modulatory effects on neural activity that may contribute to its investigational use in affective and psychotic disorders.
Current clinical data regarding valnoctamide remain limited due to its investigational status; therefore, its efficacy and safety profiles have not been fully established. No explicit details on absorption, distribution, metabolism, or excretion (ADME) parameters are publicly available, which restricts comprehensive understanding of its pharmacokinetic behavior. Similarly, safety and toxicity considerations are not well-documented, necessitating cautious evaluation in any clinical or research setting.
Valnoctamide has not been approved for marketed use and does not currently appear in widely recognized pharmaceutical products or internationally authorized brands. Its use is confined to clinical trials, and regulatory approvals have not been conferred in major jurisdictions.
When sourcing valnoctamide as an active pharmaceutical ingredient, attention to quality standards is essential given its investigational nature. Manufacturers and procurement specialists should ensure compliance with current Good Manufacturing Practices (cGMP) and verify purity, identity, and batch consistency through validated analytical methods. Traceability of raw materials and appropriate documentation are critical to support investigational and research purposes.
Identification & chemistry
| Generic name | Valnoctamide |
|---|---|
| Molecule type | Small molecule |
| CAS | 4171-13-5 |
| UNII | 3O25NRX9YG |
| DrugBank ID | DB13099 |
Formulation & handling
- Valnoctamide is a small molecule fatty amide suitable for oral formulation due to moderate water solubility and logP.
- The compound's physicochemical properties suggest stability under standard handling conditions without special sensitivity to food.
- No peptide or biologic characteristics are present, simplifying formulation and storage requirements.
Regulatory status
Valnoctamide is a type of Barbiturates
Barbiturates are a category of pharmaceutical active pharmaceutical ingredients (APIs) that have sedative, hypnotic, and anticonvulsant properties. They belong to the class of drugs called depressants, which slow down the central nervous system (CNS) activity. Barbiturates have been widely used in the medical field for their ability to induce sleep, reduce anxiety, and control seizures.
The mechanism of action of barbiturates involves enhancing the effects of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in the brain. GABA inhibits the transmission of signals between nerve cells, leading to relaxation and sedation. Barbiturates bind to specific GABA receptors, increasing the inhibitory effects of GABA and resulting in a calming effect on the CNS.
In the past, barbiturates were commonly prescribed for insomnia, anxiety disorders, and epilepsy. However, their use has decreased significantly due to the emergence of safer and more effective alternatives with fewer side effects. Nonetheless, barbiturates are still utilized in certain medical situations, such as anesthesia induction, emergency seizure control, and in some cases of refractory epilepsy.
Despite their therapeutic benefits, barbiturates carry potential risks and side effects. They can cause drowsiness, impaired coordination, and dependence when used for extended periods. Overdose of barbiturates can be life-threatening, leading to respiratory depression and coma.
In conclusion, barbiturates are a class of API widely known for their sedative, hypnotic, and anticonvulsant properties. While their use has diminished over time, they remain important in specific medical contexts. Proper caution and medical supervision are crucial when using barbiturates to ensure safety and efficacy.
